May 17, 2019 — The U.S. Food and Drug Administration (FDA) this week approved Fragmin (dalteparin sodium) injection, for subcutaneous use, to reduce the recurrence of symptomatic venous thromboembolism (VTE) in pediatric patients one month of age and older. VTE can include deep vein thrombosis (DVT) and pulmonary embolism (PE), which can lead to death.

Digital healthcare company Murj announced the availability of the Murj Analytics software-as-a-service (SaaS) platform for cardiac implantable electronic device (CIED) management. This new offering features powerful intelligence for cardiac device clinicians seeking to provide comprehensive population management through improved clinical, workforce and quality of care metrics.

At the 40th annual Heart Rhythm Scientific Sessions, May 8-11 in San Francisco, Acutus Medical announced the agreement to acquire Rhythm Xience Inc., and new strategic partnerships with Peerbridge Health, Cardiac Designs and MedFact. Acutus' expanded portfolio builds on the organization's mapping and visualization technology platform.

Preventice Solutions presented clinical data validating its BodyGuardian Remote Monitoring System with the BeatLogic deep learning platform at Heart Rhythm 2019, the Heart Rhythm Society’s 40th Annual Scientific Sessions, May 8-11 in San Francisco. This technology leverages machine learning and artificial intelligence (AI) for detection of atrial fibrillation (AF) and was validated using clinician adjudicated data.

Johnson & Johnson Medical Devices Companies announced the launch of Biosense Webster Inc.’s Cartonet to help electrophysiologists, hospitals, health systems, and researchers leverage and share data, with the goal of improving patient outcomes and operational efficiency in catheter ablation procedures. Announced at Heart Rhythm 2019, the Heart Rhythm Society's (HRS) 40th Annual Heart Rhythm Scientific Sessions, May 8-11 in San Francisco, Cartonet is the world’s first cloud-based networking and data analytics software solution for the field of electrophysiology, according to the company.

 

Johnson & Johnson Medical Devices Companies announced that Biosense Webster, Inc.’s QDot Micro catheter demonstrated safety and efficacy in achieving pulmonary vein isolation in patients with symptomatic drug-refractory paroxysmal atrial fibrillation (AF).

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now